2016-2020 Strategy: Progress, Challenges and Risks

BOARD MEETING: Anuradha Gupta, 4-5 December 2019, Delhi
Alliance on track to achieve its 2020 mission indicators

<table>
<thead>
<tr>
<th>Indicator</th>
<th>2015 Baseline</th>
<th>2020 Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under-5 mortality</td>
<td>63 per 1,000</td>
<td>57 per 1,000</td>
</tr>
<tr>
<td>Children immunised (with Gavi support)</td>
<td>198 million</td>
<td>300 million</td>
</tr>
<tr>
<td>Future deaths averted</td>
<td>4.3 million</td>
<td>5-6 million</td>
</tr>
<tr>
<td>Future DALYS averted</td>
<td>203 million</td>
<td>250 million</td>
</tr>
<tr>
<td>Vaccines sustained (after Gavi support ends)</td>
<td>N/A</td>
<td>100%</td>
</tr>
</tbody>
</table>
Dramatic decline in child deaths

Decline in under-5 mortality in Gavi supported countries

- 8.4m deaths in 2000
- 4.7m deaths in 2017
- 44% reduction

Much steeper decline in deaths from vaccine-preventable diseases

- 2m deaths in 2000
- 0.6m deaths in 2017
- 71% reduction
**Dramatic decline in child deaths**

**Steep decline in four diseases targeted by Gavi**

- **Rota**: 78% reduction in proportion of hospitalisations due to rotavirus in Madagascar
- **PCV**: nearly 50% reduction in proportion of hospitalisations due to pneumonia in Nepal

- Measles
- Rotavirus
- Hib
- Pneumococcal
- Other VPDs
Immunisation is succeeding in reaching more households, including the poorest

Highest coverage ...... and most equitable

Median coverage of key interventions in Gavi-supported countries

Coverage of services in the poorest decile in Gavi-supported countries

- DTP3 vaccination: 56%
- Careseeking for Pneumonia: 52%
- Family planning: 50%
- Antenatal care: 28%
- Sanitation: 7%

Note: based on Gavi68 with a Demographic and Health Survey or Multiple Indicator Cluster Survey, latest survey for each country, 2010-2017. Estimates are averages of country values weighted by appropriate population groups to compute weighted average coverage of a given intervention.
Zero dose child is a marker of acute inequity.

2 out of 3 zero dose children live in households surviving on less than US$ 1.90 a day.

Opportunity for multi-agency, multi-sectoral action.
SG1: Accelerate vaccines
SG2: Strengthen systems
Mixed performance: challenges and risks remain

**Coverage**
- DTP3: Fluctuating
  - 2015: 78%
  - 2016: 81%
  - 2017: 82%
  - 2018: 81%
  - 2020: 83%
  - 2015: 80%
  - 2016: 81%
  - 2017: 81%
  - 2018: 81%
  - 2020: 85%

**Breadth of Protection**
- Increasing
  - 2015: 31%
  - 2016: 39%
  - 2017: 42%
  - 2018: 52%
  - 2020: 63%

**Geographic Equity**
- Fluctuating
  - 2015: 79%
  - 2016: 81%
  - 2017: 83%
  - 2018: 81%
  - 2020: 89%

**Maternal & Wealth Equity**
- Limited Data
  - Wealth
    - 2015: 18%
    - 2016: 18%
    - 2017: 18%
    - 2018: 18%
    - 2020: 15%
  - Maternal education
    - 2015: 18%
    - 2016: 18%
    - 2017: 17%
    - 2018: 17%
    - 2020: 14%
SG 1&2: Accelerate vaccines & strengthen systems

Significant progress in expanding breadth of protection

Not just introducing vaccines but accelerating their uptake and coverage

>170m vaccinations

>300m vaccinations

Coverage (%)

2015 2016 2017 2018

HIB3  IPV  MCV2  PCV3  Rubella  Rota  YF

>300m vaccinations
Differentiation showing encouraging trends (2015-2018)

<table>
<thead>
<tr>
<th></th>
<th>Surviving Infants</th>
<th>Immunised (DTP3)</th>
<th>Under-immunised</th>
<th>Zero-dose (no DTP)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PEF Tier 1</strong></td>
<td>+1.5%</td>
<td>+5%</td>
<td>-11%</td>
<td>-16%</td>
</tr>
<tr>
<td><strong>PEF Tier 2</strong></td>
<td>+5%</td>
<td>+4%</td>
<td>+6%</td>
<td>+5%</td>
</tr>
</tbody>
</table>

**PEF Tier 1:** Nigeria, India, Pakistan, Indonesia, Ethiopia, DRC, Afghanistan, Chad, Kenya and Uganda

**PEF Tier 2 (plus fragile):** Somalia, Yemen, Mali, Mozambique, Madagascar, Niger, South Sudan, Haiti, Sudan, PNG, Myanmar, CAR, Burundi, Eritrea and Solomon Island
Progress on equity in countries where Alliance has amplified its focus

**PEF Tier 1: Pakistan**
- Under-immunised decreased by 8%
- Zero dose* decreased by 2%
- Wealth equity improved by 16pp
- Maternal education equity improved by 7pp

**Fragile: Mali**
- Under-immunised decreased by 7%
- Zero dose* decreased by 24%
- Wealth equity improved by 16pp
- Maternal education equity improved by 13pp

* Defined as no DTP
Forging new partnerships in fragile countries

SG 1&2: Accelerate vaccines & strengthen systems

SOUTH SUDAN

Health Pool Fund (HPF3) & International Organisation for Migration

SOMALIA

International Rescue Committee

AFGHANISTAN

IFRC & Afghan Red Crescent Society
SG3: Improve sustainability
Gavi continues to lead the way on sustainability

### CO-FINANCING & SELF-FINANCING

<table>
<thead>
<tr>
<th>Year</th>
<th>Co-Financing</th>
<th>Self-Financing</th>
<th>Co-Financing</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>$125m</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>$241m</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>$298m</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>$407m</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

India

### CO-FINANCING COMMITMENTS

<table>
<thead>
<tr>
<th>Year</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>85%</td>
</tr>
<tr>
<td>2016</td>
<td>100%</td>
</tr>
<tr>
<td>2017</td>
<td>100%</td>
</tr>
<tr>
<td>2018</td>
<td>100%</td>
</tr>
<tr>
<td>2020</td>
<td></td>
</tr>
</tbody>
</table>

(% of countries meeting their co-financing commitments excluding waivers)

### COUNTRIES INVESTMENT IN IMMUNISATION

- **Increasing**
  - 2015: 49%
  - 2016: 54%
  - 2017: 60%
  - 2020: 100%

(% of countries increasing domestic expenditure on RI)

### TRANSITION STATUS

- **Challenges**
  - 2015: 63%
  - 2016: 79%
  - 2017: 53%
  - 2020: 75%

(% of countries “on track” for successful transition)

SG3: Improve sustainability
Focused engagement in transitioning and transitioned countries

Transitioning countries: 5 on track, 3 not yet there

Transitioned countries showing strong performance

- 15 countries have transitioned out of Gavi support
- 14 of 15 countries have sustained above 90% or improved coverage
- All 15 countries have continued to procure vaccines introduced with Gavi support
SG4: Market shaping
Progress on price reduction and innovation; continued challenges on supply and healthy markets

**Vaccine Price Reduction**
- 2015: $20
- 2016: $19
- 2017: $17
- 2018: $16
- 2020: N/A

(Cost of full course of Penta, PCV and Rota vaccines)

**Supply Security**
- 2015: 7/11
- 2016: 9/11
- 2017: 8/11
- 2018: 8/11
- 2020: 11

(Vaccine markets where supply meets demand)

**Healthy Market Dynamics**
- 2015: 1
- 2016: 2
- 2017: 3
- 2018: 3
- 2020: 6/11

(Vaccine markets classified with moderate or high healthy dynamics)

**Vaccine Innovation**
- 2015: 0
- 2016: 3
- 2017: 5
- 2018: 7
- 2020: 10

(No. vaccines & immunisation products with improved characteristics)
Most cervical cancer deaths are in poor countries

Supply of ~35m doses versus country demand of ~80m*
13m girls reached versus 40m^ target
300k future deaths averted versus 900k target

Cervical cancer deaths, cervix uteri (per 100,000)

- ≥ 19.9
- 11.0 to 19.9
- 7.1 to 11.0
- 4.4 to 7.1
- 2.2 to 4.4
- 0 to 2.2

* Total unconstrained demand for countries that have been approved to introduce HPV vaccine between 2017-2020
^ Estimated girls to be reached by end of 2020 compared to target communicated to the Board in December 2016

Sources: GLOBOCAN 2018, IARC (http://gco.iarc.fr/today), World Health Organization
‘It always seems impossible until it is done’
Nelson Mandela

THANK YOU